AC Immune SA
Open
$3.03
Prev. Close
$3.03
High
$3.04
Low
$3.02
Market Snapshot
$295.62M
-3.3
-0.57
$32.01M
106
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
emptyResult
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Recently from Cashu
AC Immune SA Reports Promising Results for Parkinson's Immunotherapy in Phase 2 Trial
AC Immune Advances Immunotherapy for Parkinson's Disease with Promising Trial Results AC Immune SA announces promising interim results from its Phase 2 VacSYn trial for ACI-7104.056, an innovative ant…
AC Immune SA Reports Promising Phase 2 Results for Parkinson's Treatment ACI-7104.056
AC Immune Advances Parkinson's Disease Treatment with Promising Trial Results AC Immune SA announces encouraging interim results from its Phase 2 VacSYn trial for ACI-7104.056, an active immunotherapy…
AC Immune SA Reports Promising Results in Parkinson’s Disease Immunotherapy Trial
AC Immune Advances Parkinson’s Disease Treatment with Promising Trial Results AC Immune SA (NASDAQ: ACIU) announces interim safety and efficacy results from its Phase 2 VacSYn trial, focusing on ACI-7…
AC Immune SA Advances Alzheimer's Research with Promising Semorinemab Developments
AC Immune SA's Advancements in Alzheimer's Disease Research AC Immune SA, a biopharmaceutical company dedicated to neurodegenerative diseases, focuses on developing innovative therapies for Alzheimer'…